Somewhat Favorable News Coverage Somewhat Unlikely to Affect PerkinElmer (PKI) Share Price

News headlines about PerkinElmer (NYSE:PKI) have trended somewhat positive this week, according to Accern Sentiment. The research group rates the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. PerkinElmer earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave news coverage about the medical research company an impact score of 45.4762911802866 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Shares of PerkinElmer (NYSE:PKI) opened at 70.19 on Thursday. PerkinElmer has a 12-month low of $45.35 and a 12-month high of $72.11. The stock has a 50 day moving average price of $69.11 and a 200 day moving average price of $65.17. The firm has a market capitalization of $7.74 billion, a PE ratio of 21.17 and a beta of 0.72.

PerkinElmer (NYSE:PKI) last issued its quarterly earnings data on Thursday, August 3rd. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.67. The business had revenue of $547.00 million during the quarter, compared to the consensus estimate of $554.14 million. PerkinElmer had a return on equity of 13.44% and a net margin of 16.80%. The business’s revenue was up 2.0% on a year-over-year basis. During the same period in the previous year, the firm posted $0.67 earnings per share. Analysts predict that PerkinElmer will post $2.89 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 10th. Stockholders of record on Friday, October 20th will be given a dividend of $0.07 per share. The ex-dividend date is Thursday, October 19th. This represents a $0.28 annualized dividend and a dividend yield of 0.40%. PerkinElmer’s dividend payout ratio is presently 8.46%.

PKI has been the subject of a number of research analyst reports. Piper Jaffray Companies upped their target price on PerkinElmer to $80.00 and gave the company an “overweight” rating in a research report on Tuesday, July 25th. Morgan Stanley reissued an “overweight” rating and issued a $79.00 target price (up from $73.00) on shares of PerkinElmer in a research report on Monday, July 10th. Zacks Investment Research raised PerkinElmer from a “hold” rating to a “buy” rating and set a $74.00 target price for the company in a research report on Tuesday, August 1st. Evercore ISI reissued an “in-line” rating and issued a $68.00 target price (up from $62.50) on shares of PerkinElmer in a research report on Thursday, June 22nd. Finally, Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and issued a $67.00 target price on shares of PerkinElmer in a research report on Tuesday, September 26th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and five have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $67.77.

COPYRIGHT VIOLATION WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect PerkinElmer (PKI) Share Price” was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright law. The legal version of this article can be viewed at https://ledgergazette.com/2017/10/19/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-perkinelmer-pki-share-price.html.

About PerkinElmer

PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.

NYSE:PKI) opened at 70.19 on Thursday. PerkinElmer has a 12-month low of $45.35 and a 12-month high of $72.11. The stock has a 50 day moving average price of $69.11 and a 200 day moving average price of $65.17. The firm has a market capitalization of $7.74 billion, a PE ratio of 21.17 and a beta of 0.72.

PerkinElmer (NYSE:PKI) last issued its quarterly earnings data on Thursday, August 3rd. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.67. The business had revenue of $547.00 million during the quarter, compared to the consensus estimate of $554.14 million. PerkinElmer had a return on equity of 13.44% and a net margin of 16.80%. The business’s revenue was up 2.0% on a year-over-year basis. During the same period in the previous year, the firm posted $0.67 earnings per share. Analysts predict that PerkinElmer will post $2.89 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 10th. Stockholders of record on Friday, October 20th will be given a dividend of $0.07 per share. The ex-dividend date is Thursday, October 19th. This represents a $0.28 annualized dividend and a dividend yield of 0.40%. PerkinElmer’s dividend payout ratio is presently 8.46%.

PKI has been the subject of a number of research analyst reports. Piper Jaffray Companies upped their target price on PerkinElmer to $80.00 and gave the company an “overweight” rating in a research report on Tuesday, July 25th. Morgan Stanley reissued an “overweight” rating and issued a $79.00 target price (up from $73.00) on shares of PerkinElmer in a research report on Monday, July 10th. Zacks Investment Research raised PerkinElmer from a “hold” rating to a “buy” rating and set a $74.00 target price for the company in a research report on Tuesday, August 1st. Evercore ISI reissued an “in-line” rating and issued a $68.00 target price (up from $62.50) on shares of PerkinElmer in a research report on Thursday, June 22nd. Finally, Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and issued a $67.00 target price on shares of PerkinElmer in a research report on Tuesday, September 26th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and five have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $67.77.

COPYRIGHT VIOLATION WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect PerkinElmer (PKI) Share Price” was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright law. The legal version of this article can be viewed at https://ledgergazette.com/2017/10/19/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-perkinelmer-pki-share-price.html.

About PerkinElmer

PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.

Insider Buying and Selling by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply